Black Rock Inc. Magenta Therapeutics, Inc. Transaction History

Black Rock Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.62 - $0.79 $63,116 - $80,422	-101,801 Reduced 21.85%	364,168 $276,000
Q1 2023 May 12, 2023	BUY	$0.41 - $0.86 $1,202 - $2,522	2,933 Added 0.63%	465,969 $368,000
Q4 2022 Feb 13, 2023	SELL	$0.36 - $1.59 $98,946 - $437,013	-274,851 Reduced 37.25%	463,036 $185,000
Q3 2022 Nov 14, 2022	SELL	$1.26 - $2.09 $72,423 - $120,131	-57,479 Reduced 7.23%	737,887 $1.04 Million
Q2 2022 Aug 12, 2022	SELL	$0.97 - $3.08 $1.3 Million - $4.13 Million	-1,341,734 Reduced 62.78%	795,366 $955,000
Q1 2022 May 12, 2022	SELL	$2.55 - $5.23 $80,590 - $165,288	-31,604 Reduced 1.46%	2,137,100 $6.2 Million
Q4 2021 Feb 10, 2022	SELL	$4.43 - $8.33 $207,992 - $391,101	-46,951 Reduced 2.12%	2,168,704 $9.61 Million
Q3 2021 Nov 09, 2021	BUY	$6.07 - $9.89 $537,540 - $875,828	88,557 Added 4.16%	2,215,655 $16.1 Million
Q2 2021 Aug 11, 2021	BUY	$9.76 - $14.15 $20.8 Million - $30.1 Million	2,127,098 New	2,127,098 $20.8 Million

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.